piperacillin has been researched along with carbapenems in 94 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (9.57) | 18.2507 |
2000's | 12 (12.77) | 29.6817 |
2010's | 51 (54.26) | 24.3611 |
2020's | 22 (23.40) | 2.80 |
Authors | Studies |
---|---|
Jacobus, NV; Petersen, PJ; Testa, RT; Weiss, WJ | 1 |
Marumo, K; Nagaki, T; Nakamura, Y | 1 |
Livermore, DM; Yuan, M | 1 |
Blumer, JL; Bonafede, ME | 1 |
Awaya, Y; Fujiue, Y; Kodomari, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y | 1 |
Verbist, L; Verhaegen, J | 1 |
Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
Mokaddas, EM; Sanyal, SC | 1 |
Fujimura, S; Gomi, K; Honda, Y; Kikuchi, T; Kobayashi, T; Nukiwa, T; Shoji, S; Takahashi, H; Tokue, Y; Watanabe, A; Yasui, S | 1 |
Powell, LL; Wilson, SE | 1 |
Blosser-Middleton, RS; Ge, Y; Karlowsky, JA; Sahm, DF; Wikler, MA | 1 |
Adukauskiene, D; Dudzevicius, V; Ryskus, L; Sakalauskas, R; Vitkauskiene, A | 1 |
Doi, M; Fujiue, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y; Yano, S | 1 |
Donskey, CJ; Pultz, NJ; Stiefel, U | 1 |
Araujo, VR; Carvalho-Dias, VM; Cunha, CA; de Souza, CA; de Souza, M; Godoy, C; Lotfi, CJ; Maiolino, A; Nucci, M; Oliveira, AL; Pasquini, R; Ruiz, MA; Seber, A; Silla, L; Simões, BP; Tanaka, PY; Trabasso, P; Urakawa, P; Zanichelli, MA | 1 |
Aytac, S; Cengiz, AB; Cetin, M; Ceyhan, M; Secmeer, G; Tuncer, M; Yetgin, S; Yildirim, I | 1 |
Friedland, I; Kaniga, K; Ketter, N; Lee, M; Lobo, SM; Niederman, M; Prokocimer, P; Réa-Neto, A; Schroeder, E | 1 |
MacDougall, C; Oinonen, M; Pakyz, AL; Polk, RE | 1 |
Gospodarek, E; Jachna-Sawicka, K | 1 |
Restrepo, MI | 1 |
Bahram, F; Emaneini, M; Fatolahzadeh, B; Feizabadi, MM; Mehdi, FM; Mohammad, E; Morovat, T; Setareh, S; Soroush, S; Taherikalani, M | 1 |
Doherty, JA; Khan, J; Kollef, MH; Micek, ST; Pervez, M; Reichley, RM; Welch, EC | 1 |
Flamm, R; Friedland, I; Kaniga, K; Lee, M; Redman, R; Tong, SY | 1 |
Akduman, D; Ankarali, H; Aydemir, H; Celebi, G; Engin, H; Gokmen, A; Keskin, AS; Oztoprak, N; Piskin, N | 1 |
Gast, C; Ketter, N; Kollef, MH; Merchant, S; Nathwani, D; Quintana, A | 1 |
Chang, WC; Chen, CP; Chen, TL; Cho, WL; Fung, CP; Kuo, SC; Lee, YT; Siu, LK | 1 |
De Waele, JJ; Deja, M; Diaz, E; Guven, M; Koulenti, D; Lisboa, T; Mañez, R; Martin-Loeches, I; Putensen, C; Rello, J; Ulldemolins, M | 1 |
Chien, CC; Lee, CH; Li, CC; Liu, JW; Su, LH; Tang, YF | 1 |
Appelbaum, PC; Armstrong, ES; Kosowska-Shick, K; Kubo, A; Lin, G; Pankuch, GA | 1 |
Adam, HJ; DeCorby, M; Hoban, DJ; Karlowsky, JA; Rennie, R; Zhanel, GG | 1 |
Bernusset, S; Cattoen, C; Cuzon, G; Naas, T; Nordmann, P | 1 |
Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Wu, HH | 1 |
Dou, Q; Li, J; Liang, W; Liu, W; Wu, G; Wu, J; Zou, M | 1 |
Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 1 |
Falagas, ME; Ikawa, K; Tansarli, GS; Vardakas, KZ | 2 |
Chai, LY; Chee, YL; Chng, WJ; Ding, Y; Hsu, LY; Jin, J; Lee, YM; Poon, LM; Tan, LK | 1 |
Gupta, N; Rodrigues, C; Shetty, A; Soman, R | 1 |
Damas, P; Frippiat, F; Lambermont, B; Vercheval, C | 1 |
Bosnak, VK; Karaoglan, I; Mete, AO; Namiduru, M; Zer, Y | 1 |
Apisarnthanarak, A; Lye, DC; Ng, TM; Teng, CB | 1 |
Doi, Y; Qureshi, ZA | 1 |
Wu, H; Xie, W; Ye, Z; Zhang, W; Zhao, C | 1 |
Chen, YH; Chu, FY; Chuang, YC; Hsueh, PR; Huang, CC; Ko, WC; Liao, CH; Sheng, WH; Tang, HJ; Tsai, HY | 1 |
Avdic, E; Cosgrove, SE; Han, JH; Harris, AD; Hsu, AJ; Lautenbach, E; Rock, C; Tamma, PD | 1 |
Hong, MT; Seifert, CF | 1 |
Hara, T; Horiyama, T; Izawa, M; Kanazawa, S; Maki, H; Sato, T; Tsuji, M; Yamaguchi, T | 1 |
Bhattacharya, S; Bhaumik, J; Chandy, M; Goel, G; Mukherjee, S | 1 |
Azouri, T; Bathina, P; Kandipalli, D; Kaplansky, T; Kaye, KS; Lazarovitch, T; Marchaim, D; Maskit, M; Ofer-Friedman, H; Sharma, S; Shefler, C; Tal-Jasper, R; Tirosh, A; Zaidenstein, R | 1 |
Hirose, Y; Ishikawa, H; Kamata, K; Kanemoto, K; Shiotani, S; Suzuki, H; Suzuki, M; Tokuda, Y | 1 |
Arah, OA; Chow, AL; Lye, DC | 1 |
Bauernfeind, A; Schneider, I | 1 |
Chen, Y; Gao, W; Li, X; Ouyang, W; Wei, J; Wen, Z; Xue, H | 1 |
Chow, A; De, PP; Harris, PN; Khong, WX; Lye, DC; Ng, TM; Tambyah, PA | 1 |
Higuchi, H; Horikoshi, Y; Isogai, M; Ito, K; Shoji, T; Suwa, J | 1 |
Mikamo, H; Sugimoto, N; Yamagishi, Y | 1 |
Bernatoniene, J; Bielicki, JA; Doerholt, K; Gharbi, M; Goossens, H; Heginbothom, M; Lyall, H; Menson, E; Patel, SV; Paulus, S; Riordan, A; Sharland, M; Vergnano, S; Versporten, A | 1 |
Goldstein, EJ; Harrell, L; Hecht, DW; Jacobus, NV; Jenkins, SG; McDermott, LA; Newton, D; Patel, R; Snydman, DR | 1 |
Eng, LC; Kwang, LL; Ng, LS; Rao, S; Tan, TY | 1 |
Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
Alberg, T; Blix, HS; Eriksen, HM; Holen, Ø; Neteland, MI; Smith, I | 1 |
Alp, E; Çetin, M; Elmali, F; Kaynar, L; Kürkçüoglu, CA; Metan, G; Yozgat, N | 1 |
Li, B; Li, L; Peters, BM; Shirtliff, ME; Xie, J; Xu, Z; Yu, G | 1 |
Arai, K; Kato, M; Matsuoka, T; Mori, T; Ohashi, K; Shinoda, Y; Yoshida, S; Yoshimura, T | 1 |
Falagas, ME; Kofteridis, DP; Maraki, S; Mavromanolaki, VE; Perdikis, D; Samonis, G; Vardakas, KZ | 1 |
Ang, BS; Ling, LM; Lye, DC; Ng, TM; Phang, VY; Tan, MW; Tan, SH; Tay, HL; Teng, CB; Young, B | 1 |
Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
Kato, M; Matsuoka, T; Mori, T; Ohashi, K; Shinoda, Y; Tachi, T; Teramachi, H; Yoshida, S; Yoshimura, T | 1 |
Ashhurst-Smith, C; Ferguson, JK; Hughes, C | 1 |
Chakraborty, T; Fritzenwanker, M; Herold, S; Imirzalioglu, C; Wagenlehner, FM; Zimmer, KP | 1 |
Li, J; Ma, W; Sun, S; Wang, D; Yu, C | 1 |
Abdel Fattah, M; Alfaro, IG; Babich, T; Ben Ami, R; Benito, N; Beovic, B; Buhl, M; Cano, A; Cardona, R; Chazan, B; Dickstein, Y; Gibbs, J; Giske, CG; Gonzalez-Barbera, EM; Gozalo-Marguello, M; Grier, S; Haquin, J; Kofteridis, D; Landes, M; Leibovici, L; Macgowan, A; Machuca, I; Maraki, S; Martinez Martinez, L; Mauer, S; McCarthy, K; Morales, I; Mueller-Premru, M; Naucler, P; Nesher, L; Oliver, A; Pagani, L; Paterson, DL; Paul, M; Pulcini, C; Rivera, A; Rodriguez-Bano, J; Ruiz De Gopegui, E; Saje, A; Salavert, M; Tacconelli, E; Valik, JK; Vitrat, V; Weissman, Y; Yahav, D; Yanovskay, A; Zacharioudaki, M; Zaidman-Shimshovitz, A | 1 |
Busch, DH; Katchanov, J; Lahmer, T; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Wantia, N; Waschulzik, B | 1 |
Lai, CC; Wang, JH | 1 |
Academia, EC; Jenrette, JE; McLaughlin, JM; Mueller, SW | 1 |
Chusri, S; Ontong, JC; Ozioma, NF; Voravuthikunchai, SP | 1 |
Avery, TM; Boone, RL; Chambers, SA; Damo, SM; Dent, L; Doster, RS; Francis, JD; Gaddy, JA; Guevara, MA; Lu, J; Manning, SD; Marshall, D; Moore, RE; Townsend, SD; Whitehead, B | 1 |
Asai, N; Hagihara, M; Kato, H; Koizumi, Y; Mikamo, H; Ohashi, W; Sakanashi, D; Shibata, Y; Shiota, A; Suematsu, H; Watanabe, H; Yamagishi, Y | 1 |
Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
Ang, B; Ang, LW; Chua, BH; Heng, ST; Lee, TH; Lin, R; Lye, DC; Ng, TM; Quek, J; Tan, SH; Tay, HL; Teng, CB; Yap, MY; Young, BE | 1 |
Annane, D; Bonten, MJM; Carneiro, J; Deja, M; Estevez, F; Harbarth, S; Jereb, M; Jorens, PG; Lawrence, C; Rothbart, A; Schedler, D; Seme, K; Šifrer, F; Spöhr, F; Tomič, V; van Duijn, PJ; Verbrugghe, W | 1 |
Braun-Feldweg, J; Germer, CT; Lock, JF; Meyer-Sautter, P; Rüsch, J; Surat, G | 1 |
Bauer, MJ; Flora, MS; Forde, BM; Habib, ZH; Harris, P; Islam, K; Roberts, JA; Shirin, T; Sime, FB; Wallis, SC | 1 |
Deligios, M; Fiamma, M; Paglietti, B; Rubino, S; Sacarlal, J; Santona, A; Simbine, SE; Sumbana, JJ; Taviani, E; Zimba, T | 1 |
Dong, L; Feng, J; Geng, H; Gu, S; He, C; Hou, G; Ji, T; Kang, W; Lai, J; Li, Y; Li, Z; Pang, D; Wang, Y; Zhao, L; Zhu, X; Zhu, Y | 1 |
Abduljabbar Jaloob Aljanaby, A; Abduljabbar Jaloob Aljanaby, I; Hayder Hasan, T; Yahya Abdulla, N | 1 |
Assanelli, AA; Bernardi, M; Carletti, S; Carrabba, MG; Castagna, A; Ciceri, F; Clerici, D; Corti, C; Erbella, F; Farina, F; Galli, L; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Lugli, AP; Lupo Stanghellini, MT; Mancini, N; Mastaglio, S; Nitti, R; Oltolini, C; Peccatori, J; Poli, A; Ripa, M; Ruggeri, A; Scarpellini, P; Tassan Din, C; Xue, E | 1 |
Gill, CM; Nicolau, DP | 1 |
Dalğıç, D; Kandemir, T; Nağıyev, T; Üçkayabaşı, A | 1 |
Behera, DU; Das, A; Dey, S; Dixit, S; Gaur, M; Sahoo, RK; Sahoo, S; Sahu, A; Subudhi, E | 1 |
Banjara, MR; Devkota, MD; Pokhrel, BM; Sharma, S | 1 |
Bercot, B; Bernier, J; Bleibtreu, A; Chaibi, K; Contejean, A; Cuzon, G; Delory, T; El Alaoui, F; Escaut, L; Joseph, A; Lafaurie, M; Maillard, A; Molina, JM; Paccoud, O; Poupet, H; Robert, J; Surgers, L; Tankovic, J; Villa, A | 1 |
Cao, SS; Cui, B; Cui, F; Cui, J; Fan, BY; Fan, TT; Guan, Y; Ji, B; Li, MY; Li, SR; Wang, JW; Wang, L; Yan, CY; Zhang, W | 1 |
Ali, MG; Almoneim, ZA; Kareem, SM | 1 |
6 review(s) available for piperacillin and carbapenems
Article | Year |
---|---|
Role of newer broad-spectrum beta-lactam and fluoroquinolone antibiotics in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbapenems; Cephalosporins; Child; Child, Preschool; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Molecular Structure; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Ticarcillin | 1996 |
The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection.
Topics: Abdomen; Abdominal Abscess; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; Carbapenems; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Surgical Wound Infection; Ticarcillin | 2000 |
Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; Carbapenems; Drug Administration Schedule; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome | 2013 |
Escherichia coli sequence type 131: epidemiology and challenges in treatment.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Cystitis; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; United States | 2014 |
Treatment Options for Carbapenem- Resistant Gram-Negative Infections.
Topics: Aminoglycosides; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Therapy, Combination; Escherichia coli; Fluoroquinolones; Fosfomycin; Germany; Gram-Negative Bacteria; Humans; Klebsiella pneumoniae; Piperacillin; Pseudomonas aeruginosa; Tigecycline | 2018 |
Comparison of Duration and Empiric Antibiotic Choice of Post-Operative Treatment in Abdominal Sepsis.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Intraabdominal Infections; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis | 2022 |
4 trial(s) available for piperacillin and carbapenems
Article | Year |
---|---|
Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Carbapenems; Child; Child, Preschool; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2008 |
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Cross Infection; Doripenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Tazobactam; Treatment Outcome | 2008 |
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Carbapenems; Drug Eruptions; Drug Therapy, Combination; Female; Fever; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Survival Rate; Young Adult | 2010 |
The effects of antibiotic cycling and mixing on acquisition of antibiotic resistant bacteria in the ICU: A post-hoc individual patient analysis of a prospective cluster-randomized crossover study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross-Over Studies; Gram-Negative Bacteria; Humans; Intensive Care Units; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Tazobactam | 2022 |
84 other study(ies) available for piperacillin and carbapenems
Article | Year |
---|---|
In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.
Topics: Amikacin; Animals; Bacterial Infections; Bacteroides fragilis; Carbapenems; Ceftazidime; Cilastatin; Ciprofloxacin; Dipeptidases; Drug Therapy, Combination; Escherichia coli; Female; Imipenem; Klebsiella pneumoniae; Metronidazole; Mice; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Staphylococcus; Streptococcus; Thienamycins | 1991 |
Evaluation of high-level carbapenem resistance in atypical Serratia marcescens by a comparison with its revertants.
Topics: Carbapenems; Cell Membrane Permeability; Drug Resistance, Microbial; Evaluation Studies as Topic; Imipenem; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Penicillins; Piperacillin; Serratia marcescens; Thienamycins | 1996 |
Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Intensive Care Units; Klebsiella; Klebsiella Infections; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Tazobactam | 1996 |
[The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serotyping; Sputum; Thienamycins | 1998 |
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefaclor; Cefadroxil; Cefatrizine; Cefepime; Cefixime; Cefotaxime; Cefpirome; Cefpodoxime; Ceftazidime; Ceftibuten; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cephradine; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pneumococcal Infections; Serotyping; Species Specificity; Streptococcus pneumoniae | 1998 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
Topics: Carbapenems; Cross Infection; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Incidence; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Risk Factors | 1999 |
[In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
Topics: Bacteria; Carbapenems; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Penicillins; Piperacillin; Respiratory Tract Infections; Thienamycins; Time Factors | 1999 |
In vitro antimicrobial activity of doripenem, a new carbapenem.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Cephalosporins; Doripenem; Drug Therapy, Combination; Enterobacteriaceae; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam | 2004 |
[The rate of isolation of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and resistance to antibiotics].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; Bronchi; Carbapenems; Cephalosporins; Ciprofloxacin; Gentamicins; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin | 2006 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Meropenem; Oxazines; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Urine | 2006 |
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
Topics: Animals; beta-Lactams; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Enterococcus; Ertapenem; Female; Imipenem; Intestines; Klebsiella pneumoniae; Mice; Piperacillin; Sodium Chloride; Time Factors; Vancomycin Resistance | 2007 |
Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Brazil; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple; Female; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infant; Male; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Prospective Studies; Risk Factors | 2007 |
Trends in antibacterial use in US academic health centers: 2002 to 2006.
Topics: Academic Medical Centers; Adult; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; United States; Vancomycin | 2008 |
[Evaluation of occurrence of Alcaligenes faecalis in clinical samples of patients of the university hospital in Bydgoszcz].
Topics: Alcaligenes faecalis; Carbapenems; Drug Resistance, Bacterial; Environmental Microbiology; Environmental Monitoring; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Suppuration; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination; Urine | 2009 |
Efficacy of intravenous infusion of doripenem.
Topics: Carbapenems; Cross Infection; Doripenem; Humans; Imipenem; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated | 2009 |
Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran hospitals.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefotaxime; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Humans; Imipenem; Iran; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2009 |
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Shock, Septic | 2010 |
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Ciprofloxacin; Clinical Trials, Phase III as Topic; Doripenem; Enterobacteriaceae; Enterobacteriaceae Infections; Global Health; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence | 2010 |
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Female; Health Resources; Humans; Imipenem; Length of Stay; Male; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2010 |
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Promoter Regions, Genetic; Recombination, Genetic; Sequence Analysis, DNA; Species Specificity; Tazobactam | 2010 |
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Colistin; Cross Infection; Europe; Female; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Piperacillin; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Quinolones; Respiration, Artificial; Severity of Illness Index; Treatment Outcome | 2011 |
Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Case-Control Studies; Ciprofloxacin; Female; Humans; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Young Adult | 2010 |
Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Doripenem; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa | 2011 |
Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Blood; Canada; Candida; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Drug Resistance, Fungal; Emergency Service, Hospital; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Infant, Newborn; Intensive Care Units; Microbial Sensitivity Tests; Middle Aged; Outpatient Clinics, Hospital; Patients' Rooms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Prevalence; Sepsis | 2011 |
First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France.
Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Enterobacter cloacae; Enterobacteriaceae Infections; France; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam | 2012 |
Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli.
Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2016 |
[Molecular epidemiological characteristics of clinically isolated carbapenem-resistant Acinetobacter baumannii in Changsha].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Carbapenems; China; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Molecular Epidemiology; Piperacillin; Polymerase Chain Reaction | 2012 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital.
Topics: Academic Medical Centers; Adult; Bacteremia; Carbapenems; Ceftazidime; Drug Resistance, Multiple; Febrile Neutropenia; Female; Gram-Negative Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prevalence; Prospective Studies; Risk Factors; Sepsis; Singapore; Tazobactam; Treatment Outcome; Universities | 2012 |
Reply to Soman et al and Frippiat et al.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Female; Humans; Male; Penicillanic Acid; Piperacillin; Sepsis | 2013 |
Are prolonged/continuous infusions of β-lactams for all?
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Female; Humans; Male; Penicillanic Acid; Piperacillin; Sepsis | 2013 |
Is extended or continuous infusion of carbapenems the obvious solution to improve clinical outcomes and reduce mortality?
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Humans; Penicillanic Acid; Piperacillin | 2013 |
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Carbapenems; Cefoperazone; Colistin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Tigecycline | 2013 |
A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacteremia; Carbapenems; Case-Control Studies; Central Venous Catheters; Cephalosporins; Coinfection; Drug Resistance, Bacterial; Female; Humans; Male; Microbial Sensitivity Tests; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Respiratory Tract Infections; Risk Factors; Severity of Illness Index; Treatment Outcome | 2014 |
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Drug Resistance; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2014 |
Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cohort Studies; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella oxytoca; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Proportional Hazards Models; Proteus mirabilis; Survival Rate; Time Factors | 2015 |
Clinical Impact of Discordant Prescribing of Fluoroquinolones and Alternative Treatments in Escherichia coli Pyelonephritis.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Drug Resistance, Bacterial; Escherichia coli Infections; Female; Fluoroquinolones; Guidelines as Topic; Humans; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Treatment Outcome | 2016 |
Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Colony Count, Microbial; Doripenem; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Hydrolysis; Microbial Sensitivity Tests; Mutation Rate; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; RNA, Messenger | 2015 |
Epidemiology of antimicrobial resistance in an oncology center in eastern India.
Topics: Acinetobacter; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Cancer Care Facilities; Carbapenems; Ceftazidime; Ciprofloxacin; Clindamycin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacteriaceae; Feces; Fluconazole; Gentamicins; Humans; India; Methicillin-Resistant Staphylococcus aureus; Mycoses; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Yeasts | 2015 |
Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Hospital Mortality; Humans; Intraabdominal Infections; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections | 2015 |
Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Community-Acquired Infections; Cross Infection; Female; Hospital Mortality; Humans; Male; Middle Aged; Needs Assessment; Organizational Policy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prognosis; Pseudomonas Infections | 2015 |
Patient and physician predictors of patient receipt of therapies recommended by a computerized decision support system when initially prescribed broad-spectrum antibiotics: a cohort study.
Topics: Academic Medical Centers; Aged; Anti-Bacterial Agents; Carbapenems; Cohort Studies; Decision Support Systems, Clinical; Drug Therapy, Computer-Assisted; Drug Utilization; Female; Guideline Adherence; Humans; Inappropriate Prescribing; Intensive Care Units; Kidney Diseases; Male; Middle Aged; Patient Admission; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; Singapore | 2016 |
Intrinsic carbapenem-hydrolyzing oxacillinases from members of the genus Pandoraea.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Imipenem; Piperacillin | 2015 |
Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6-year epidemiological study in southern China.
Topics: Anti-Bacterial Agents; Carbapenems; China; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterococcus faecalis; Epidemiologic Studies; Escherichia coli; Female; Gentamicins; Humans; Intraabdominal Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome | 2016 |
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2016 |
Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Hospitals; Humans; Japan; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tokyo | 2016 |
Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Female; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam | 2017 |
Using a simple point-prevalence survey to define appropriate antibiotic prescribing in hospitalised children across the UK.
Topics: Adolescent; Anti-Bacterial Agents; Carbapenems; Child; Child, Hospitalized; Child, Preschool; Cross-Sectional Studies; Drug Prescriptions; Drug Resistance, Microbial; Drug Utilization; Female; Health Care Surveys; Hospitalization; Hospitals; Humans; Inappropriate Prescribing; Infant; Male; Pediatrics; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Patterns, Physicians'; State Medicine; Surveys and Questionnaires; United Kingdom | 2016 |
Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
Topics: Anti-Infective Agents; Bacteroides; Bacteroides fragilis; Bacteroides Infections; Bacteroidetes; beta-Lactamase Inhibitors; Carbapenems; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; United States | 2017 |
Clinical characteristics and antimicrobial susceptibilities of anaerobic bacteremia in an acute care hospital.
Topics: Anaerobiosis; Anti-Infective Agents; Bacteremia; Bacteria, Anaerobic; Bacteroides; Carbapenems; Clindamycin; Clostridium; Drug Resistance, Microbial; Fusobacterium; Gram-Positive Bacteria; Humans; Intraabdominal Infections; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propionibacterium; Retrospective Studies | 2017 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Broad-spectrum antibiotics in Norwegian hospitals.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbapenems; Cephalosporins; Cross Infection; Cross-Sectional Studies; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization Review; Guideline Adherence; Hospitals; Humans; Norway; Piperacillin; Quinolones; Respiratory Tract Infections | 2017 |
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Febrile Neutropenia; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Teicoplanin; Tertiary Care Centers; Treatment Outcome; Turkey; Vancomycin | 2017 |
Clinical features and antimicrobial resistance profiles of important Enterobacteriaceae pathogens in Guangzhou representative of Southern China, 2001-2015.
Topics: Amikacin; Anti-Bacterial Agents; Blood; Carbapenems; Ceftazidime; Cephalosporins; China; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Enterobacter; Enterobacteriaceae; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sputum; Urinary Tract | 2017 |
Effectiveness of a Computer-facilitated, Pharmacist-driven Antimicrobial Stewardship Program for Infection Management.
Topics: Anti-Bacterial Agents; Carbapenems; Computer Systems; Cost Savings; Databases, Factual; Drug Monitoring; Drug Utilization; Drug Utilization Review; Humans; Infection Control; Methicillin-Resistant Staphylococcus aureus; Monitoring, Physiologic; Penicillanic Acid; Pharmacists; Piperacillin; Tazobactam | 2017 |
In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Child; Colistin; Drug Resistance, Multiple, Bacterial; Enterobacter; Enterobacteriaceae Infections; Greece; Hospitals, University; Humans; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tigecycline | 2017 |
Clinical impact of non-antibiotic recommendations by a multi-disciplinary antimicrobial stewardship team.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Communicable Diseases; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Evaluation of antimicrobial stewardship (AS) for appropriate use of antimicrobial agents.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Hospital Mortality; Hospitalization; Humans; Length of Stay; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Services; Pharmacists; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections | 2017 |
Gram negative anaerobe susceptibility testing in clinical isolates using Sensititre and Etest methods.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbapenems; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2018 |
In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefoperazone; Ceftazidime; China; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftazidime; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2020 |
Antimicrobial resistance of bacteraemia in the emergency department of a German university hospital (2013-2018): potential carbapenem-sparing empiric treatment options in light of the new EUCAST recommendations.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Drug Resistance, Bacterial; Emergency Service, Hospital; Enterobacteriaceae; Germany; Hospitals, University; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Retrospective Studies; Staphylococcus aureus; Tazobactam; Treatment Outcome | 2019 |
Is Piperacillin-Tazobactam Really Comparable to Carbapenem for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?
Topics: beta-Lactamases; Carbapenems; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis | 2020 |
Evaluation of First-Dose, Intravenous Push Penicillins and Carbapenems in the Emergency Department.
Topics: Ampicillin; Anti-Bacterial Agents; Carbapenems; Emergency Service, Hospital; Ertapenem; Humans; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sulbactam | 2022 |
Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fluoroquinolones; Fosfomycin; Klebsiella pneumoniae; Piperacillin; Tetracyclines | 2021 |
Analysis of virulence phenotypes and antibiotic resistance in clinical strains of Acinetobacter baumannii isolated in Nashville, Tennessee.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Physiological; Anti-Bacterial Agents; Carbapenems; Catheters; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Phenotype; Piperacillin; Sputum; Tennessee; Urine; Wounds and Injuries | 2021 |
Ceftriaxone versus tazobactam/piperacillin and carbapenems in the treatment of aspiration pneumonia: A propensity score matching analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Aspiration; Propensity Score; Retrospective Studies | 2021 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Sustaining Antimicrobial Stewardship in a High-Antibiotic Resistance Setting.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Cohort Studies; Drug Resistance, Microbial; Humans; Piperacillin; Prospective Studies; Tazobactam | 2022 |
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Extraintestinal Pathogenic Escherichia coli; Gentamicins; Hospitals; Humans; Iron; Mozambique; Piperacillin; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Drug resistance characteristics and molecular typing of Escherichia coli isolates from neonates in class A tertiary hospitals: A multicentre study across China.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Carbapenems; Cefotaxime; Child; Ciprofloxacin; Doxycycline; Drug Resistance; Escherichia coli; Escherichia coli Infections; Female; Humans; Infant, Newborn; Microbial Sensitivity Tests; Multilocus Sequence Typing; Piperacillin; Pregnancy; Tazobactam; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Assessment of ß-lactams and Carbapenems Antimicrobials Resistance in
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ceftazidime; Cephamycins; Cloxacillin; Humans; Iraq; Klebsiella oxytoca; Lactams; Microbial Sensitivity Tests; Piperacillin; Urinary Tract Infections | 2022 |
Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.
Topics: Anti-Infective Agents; Carbapenems; Cohort Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Neutropenia; Piperacillin; Retrospective Studies; Tazobactam; Transplantation, Homologous | 2023 |
Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
Topics: Anti-Bacterial Agents; Carbapenems; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Mitomycin; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam | 2023 |
[Relationship of Hypervirulent Capsular Genotypes of Klebsiella pneumoniae with Antibiotic Susceptibility and Beta-Lactamase Genes].
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clavulanic Acid; Colistin; Drug Resistance, Bacterial; Genotype; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin; Tazobactam | 2023 |
Urban wastewater contributes to the emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) in an urban receiving river in eastern India.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; India; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin; Rivers; Wastewater | 2023 |
Prevalence of Multidrug Resistant Pseudomonas aeruginosa Isolated from Clinical Specimens in Tertiary Care Hospital.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Humans; Microbial Sensitivity Tests; Nepal; Piperacillin; Prevalence; Pseudomonas aeruginosa; Tazobactam; Tertiary Care Centers | 2023 |
Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cephalosporins; Humans; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2023 |
Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Urinary Tract Infections | 2023 |
Evaluated gene expressions of Metallo beta lactamase genes GIM and , VIM, SPM in Pseudomonas aeruginosa clinical isolates.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Ciprofloxacin; Gene Expression; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Real-Time Polymerase Chain Reaction; RNA, Ribosomal, 16S | 2023 |